Scholar Rock to Present at 1st William Blair and Westwicke Partners Biotechnology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock, a biotechnology company focused on discovering and developing niche modulators that selectively target growth factor activation in the disease microenvironment, today announced that Nagesh Mahanthappa, Ph.D., President and Chief Executive Officer of Scholar Rock, will participate in the 1st William Blair and Westwicke Partners Biotechnology Pre-IPO/Crossover Conference on Thursday, July 9, 2015, in New York City.

About Scholar RockScholar Rock is a biotechnology company focused on discovering and developing niche modulators, a novel class of biologic therapies that selectively modulate the activation of growth factors in the disease microenvironment. The Company’s initial proprietary and partnered drug discovery programs target specific growth factors, including members of the TGF-beta superfamily, which are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems and autoimmune diseases. Scholar Rock was founded based on discoveries made by its scientific founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, of Boston Children's Hospital and Harvard Medical School, related to the molecular mechanisms of growth factor activation. The company is backed by leading life sciences investors, including Polaris Partners, ARCH Venture Partners, Timothy Springer, EcoR1 Capital and The Kraft Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701005440/en/

Investor Contact:
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
[email protected]
or
Media Contact:
The Yates Network
Kathryn Morris, 845-635-9828
[email protected]

Source: Scholar Rock

You May Also Be Interested In

• Inside information: Meriaura Group's board has conditionally decided to sell Meriaura's minority ownership to Meriaura Invest to rearrange the group's financing
• Pre-Investor Call Presentation available to shareholders
• Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio